APR 30 2026
Axsome Therapeutics — Auvelity (dextromethorphan/bupropion) $AXSM
for Agitation in Alzheimer's dementia
FDA approved Auvelity (dextromethorphan/bupropion) for agitation associated with dementia due to Alzheimer's disease.
About
Alzheimer's disease is a neurodegenerative condition that causes memory loss and can lead to severe behavioral issues like agitation, mood swings, and social withdrawal. Auvelity is a combination of two drugs, dextromethorphan and bupropion, which work together to increase activity in brain pathways involved in mood and stress regulation. This may help calm the agitation that often accompanies Alzheimer's, potentially improving daily life for those affected.
Pivotal trial
This study will evaluate the long-term safety and efficacy of AXS-05 in subjects with Alzheimer's disease (AD) agitation.
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on Auvelity
- Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference - Yahoo Finance
- Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer’s Launch Gains Traction - MarketBeat
- Axsome's Auvelity Launch Shows Early Strength in Alzheimer's Agitation, RBC Says - Yahoo Finance
- AXSM: AUVELITY's growth accelerates in new indications, with strong pipeline and financial outlook - tradingview.com
- AXSM Jumps 6% As Mizuho Calls Auvelity’s Alzheimer’s Launch A ‘Strong Start’ - Stocktwits
Sponsor Watch — recent news on Axsome Therapeutics
- Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day
- Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer’s Launch Gains Traction
- Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference
- Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
- AXSM Jumps 6% As Mizuho Calls Auvelity’s Alzheimer’s Launch A ‘Strong Start’